FMP
Royalty Pharma plc
RPRX
NASDAQ
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
32.45 USD
0.16 (0.493%)
Historical Prices
From:
To:
About
ceo
Mr. Sandy Balkin Ph.D.
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematol...
CIK
0001802768
ISIN
GB00BMVP7Y09
CUSIP
G7709Q104
Address
110 East 59th Street
Phone
212 883 0200
Country
US
Employee
75
IPO Date
Jun 16, 2020
Financial Statement
Earnings
RPRX Financial Summary
CIK
0001802768
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
G7709Q104
ISIN
GB00BMVP7Y09
Country
US
Price
32.45
Beta
0.49
Volume Avg.
4.76M
Market Cap
14.06B
Shares
-
52-Week
24.05-34.2
DCF
25.06
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
16.99
P/B
-
Website
https://www.royaltypharma.com
Upgrades and Downgrades
Rating Distribution
TheFly
19 days ago
Mar 28, 2025
Buy
Buy
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest RPRX News
Seeking Alpha
Aug 22, 2024
Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Ratin...
Vertex franchise poses a significant downside risk. That said, Royalty Pharma has solid execution capabilities and is diversifying earnings with new investments. The company raised its 2024 outlook after three quarters of double-digit growth. A solid team, a balance sheet with M&A maneuvers, and an impressive track record make the company a buy.
Seeking Alpha
Aug 11, 2024
Royalty Pharma: Busy Putting Capital To Work
Royalty Pharma's stock has underperformed recently, down 7% year to date while the S&P500 has climbed 13%. In the company's latest Q2'24 results, Royalty Pharma reported a 12% increase in portfolio receipts, driven by sales growth from its cystic fibrosis franchise and other drugs. The company has also been active in acquiring new royalties and investing in various therapeutic areas and is on track to exceed deployment targets.
Zacks Investment Research
Aug 8, 2024
Royalty Pharma (RPRX) Q2 Earnings: How Key Metrics Compare t...
The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks Investment Research
Aug 8, 2024
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates
Royalty Pharma (RPRX) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of $0.95 per share. This compares to earnings of $0.85 per share a year ago.
Zacks Investment Research
Jul 19, 2024
These 2 Finance Stocks Could Beat Earnings: Why They Should ...
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
GlobeNewsWire
Jul 19, 2024
Royalty Pharma to Announce Second Quarter 2024 Financial Res...
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
Zacks Investment Research
Jul 17, 2024
Royalty Pharma (RPRX) Recently Broke Out Above the 50-Day Mo...
From a technical perspective, Royalty Pharma (RPRX) is looking like an interesting pick, as it just reached a key level of support. RPRX recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
Zacks Investment Research
Jul 15, 2024
Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next ...
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
